Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future (Advances in Predictive, Preventive and Personalised Medicine Book 2)

This book will compile a collection of chapters dedicated to varied aspects of PPPM in neuropsychiatric and neurodegenerative diseases. Among the topics to be covered are: Recent advances in ALS research News about Clinical aspects and advanced therapy approaches in personalized treatment of ALS Schizophrenia: New treatments and clinical aspects Predictive, Preventive and Personalised Medicine in aging macular degeneration Advances in Multiple Sclerosis Pharmacogenetics, Tailoring Treatment Efficacy, Safety and Regimen Selection Multiple sclerosis related biomarkers: perspectives for clinical application Preventive clinical trials in brain aging: new trends & the need of guidelines MCI_ clinical guidelines in early diagnosis of dementia Alzheimer's disease: diagnostics, prognostics and the road to prevention Biomarkers for early diagnosis of Parkinson's and Alzheimer's diseases Synucleinopathies, tauopathies, TDP-43 proteinopathies and amyloidosis PSP, MSA and other parkinsonisms Front Matter....Pages i-xvii Front Matter....Pages 1-1 Time for New Guidelines in Handling of Neurodegenerative Disorders: Optimistic Versus Pessimistic Prognosis by Application of PPPM....Pages 3-9 Front Matter....Pages 11-11 Individual Predispositions in Healthy Vasospastic Individuals: Patient Profiling for Targeted Prevention of “Down-Stream” Pathologies as Cost-Effective Personalised Medicine....Pages 13-29 Idiopathic REM Sleep Behavior Disorder as a Long-Term Predictor of Neurodegenerative Disorders....Pages 31-44 New Animal Models of Progressive Neurodegeneration: Tools for Developing Predictive Diagnostics and Identifying Presymptomatic Therapeutic Targets....Pages 45-68 Tau Pathology: A Selected View on the Current Status....Pages 69-92 Front Matter....Pages 93-93 The Use of Biomarkers for Prediction and Prevention of Alzheimer’s and Parkinson’s Diseases....Pages 95-140 Clinical Trials of AD Delay of Onset: Enrichment by a Prognostic Genetic Biomarker....Pages 141-160 An Update on CSF Biomarkers of Parkinson’s Disease....Pages 161-184 Front Matter....Pages 185-185 Glaucomatous Optic Neuropathy: Risk Assessment and Potential Targets for Effective Prevention and Treatments Tailored to the Patient....Pages 187-201 Front Matter....Pages 203-203 Toward a Personalized Approach in Amyotrophic Lateral Sclerosis: New Developments in Diagnosis, Genetics, Pathogenesis and Therapies....Pages 205-233 Recent Advances in ALS Research: Perspectives for Personalized Clinical Application....Pages 235-274 Front Matter....Pages 275-275 Exercise in Multiple Sclerosis – An Integral Component of Disease Management....Pages 277-299 Bridging the Informatics Gap Between Bench and Bedside: Implications to Neurodegenerative Diseases....Pages 301-308 Front Matter....Pages 309-309 Personalized Medicine in Rare Pediatric Neurometabolic Diseases....Pages 311-327 Back Matter....Pages 329-396 The economic burden of dementia was estimated as being US$ 604 billion in 2010. Now it is time for new guidelines in handling of neurodegenerative disorders. Optimistic versus Pessimistic Prognosis depends much on diagnostic and treatment approaches which healthcare will preferably adopt in the near future. Current dramatic situation can be significantly improved by the implementation of appropriate early diagnostic, targeted preventive measures and therapies tailored to the person advancing healthcare and enhancing the patient life quality. Neurodegenerative Diseases are pathologies of multi-factorial nature involving interplay of epi/genetic and environmental risk factors. Insights into molecular pathomechanisms will enable to create the most effective neuro-protective strategies and individualised treatment before manifest pathology. Utilization of the advanced integrative medical approach could enable a significant portion of population to reach the 100-year age limit remaining vibrant in excellent physical and mental health as actively contributing members of the society. The crucial role of the integrative approach by PPPM has been acknowledged as priorities by World Health Organization, United Nations and the European Union among others. Extensive efforts of international consortia are essential in the field to consolidate the accumulated expertise and to create population screening, robust diagnostic approaches, effective prevention in groups at high risk and targeted treatments. This book volume "Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future" is intended to serve as a reference source for basic researchers and healthcare industry involved in the field of neurosciences with a special emphasis on mental health promotion and innovations intended to delay or even prevent neurodegenerative diseases